A heated takeover battle has erupted around generic-drug company Actavis Inc. as industry players seek to shore themselves up amid increasing competition and fewer new knock-off-drug opportunities.

Valeant Pharmaceuticals International Inc. and Mylan Inc. are evaluating their options after approaches they made for Parsippany, N.J.-based Actavis were rebuffed, according to people familiar with the matter.